PDCD1 and small cell lung carcinoma: Although SCLC cells display scant PD-L1 (~5%), 18.5–56.3% of intratumoral immune cells express PD-L1, implicating this stromal ligand as a key mediator of immune evasion and a critical target for PD-1/PD-L1-directed therapy.